Quick Answer
Aprea Therapeutics, Inc. reported Net Income of -$12.60 million for fiscal year 2025.
Aprea Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$12.60M +2.8% |
-$12.96M +9.3% |
-$14.29M +87.3% |
-$112.66M -203.4% |
-$37.13M +30.6% |
-$53.48M -90.6% |
| Diluted EPS | -$1.93 +17.9% |
-$2.35 +40.5% |
-$3.95 +94.2% |
-$67.99 -94.9% |
-$34.88 +31.1% |
-$50.61 -983.7% |
| Total Assets | $15.93M -33.6% |
$23.98M +5.9% |
$22.65M -24.9% |
$30.16M -46.9% |
$56.82M -38.8% |
$92.81M -30.5% |
| Cash and Equivalents | $14.60M -36.1% |
$22.85M +5.8% |
$21.61M -24.9% |
$28.79M -45.8% |
$53.08M -40.4% |
$89.02M -31.6% |
| Stockholders Equity | $12.44M -35.6% |
$19.31M +13.9% |
$16.95M -33.9% |
$25.64M -48.2% |
$49.51M -36.0% |
$77.40M -37.7% |
| R&D Expense | — | — | — | — | $23.90M -36.9% |
$37.88M +80.8% |
| Operating Income | -$13.23M +7.6% |
-$14.32M +7.4% |
-$15.47M +86.4% |
-$113.39M -202.8% |
-$37.45M | — |
| Shares Outstanding | 8.19M +49.5% |
5.48M +46.7% |
3.74M +40.7% |
2.66M +142.9% |
1.09M -94.8% |
21.19M +0.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.97M | +21.4% | +8.2% |
| Diluted EPS | September 30, 2025 | -$0.47 | +26.6% | +11.3% |
| Total Assets | September 30, 2025 | $14.32M | -46.7% | -17.3% |
| Cash and Equivalents | September 30, 2025 | $13.72M | -47.7% | -17.0% |
| Stockholders Equity | September 30, 2025 | $10.91M | -50.3% | -18.6% |
| R&D Expense | March 31, 2022 | $4.09M | -39.5% | -32.0% |
| Operating Income | September 30, 2025 | -$3.12M | +23.9% | +8.0% |
| Shares Outstanding | September 30, 2025 | 5.98M | +10.0% | +3.9% |
- Aprea Therapeutics, Inc. reported Net Income of -$12.60 million for fiscal year 2025.
- Aprea Therapeutics, Inc. showed an increase of +2.8% in Net Income compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Diluted EPS of $1.93 per share (loss) for fiscal year 2025.
- Aprea Therapeutics, Inc. showed an increase of +17.9% in Diluted EPS compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Total Assets of $15.93 million for fiscal year 2025.
- Aprea Therapeutics, Inc. showed a decrease of -33.6% in Total Assets compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Cash and Equivalents of $14.60 million for fiscal year 2025.
- Aprea Therapeutics, Inc. showed a decrease of -36.1% in Cash and Equivalents compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Stockholders Equity of $12.44 million for fiscal year 2025.
- Aprea Therapeutics, Inc. showed a decrease of -35.6% in Stockholders Equity compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported R&D Expense of $23.90 million for fiscal year 2021.
- Aprea Therapeutics, Inc. showed a decrease of -36.9% in R&D Expense compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Operating Income of -$13.23 million for fiscal year 2025.
- Aprea Therapeutics, Inc. showed an increase of +7.6% in Operating Income compared to the prior fiscal year.
- Aprea Therapeutics, Inc. reported Shares Outstanding of 8.19 million shares for fiscal year 2025.
- Aprea Therapeutics, Inc. showed an increase of +49.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: